Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

David Olmos Hidalgo

Group leader, distinguished investigator

Instituto de Investigación Hospital 12 de Octubre

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Medical Imaging Medical Imaging professors in Spain

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (15)

Francesco Grussu

Senior Investigator

Vall d'Hebron Institute of Oncology

SPAIN

View details

Enrique Gonzalez-Billalabeitia

Universidad Católica de Murcia (UCAM)

SPAIN

View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA

View details

Satoru Kawakami

Professor

Saitama Medical Center

JAPAN

View details

Johann S de Bono

Head of Clinical Studies Division

Institute of Cancer Research

UNITED KINGDOM

View details

Stéphane Oudard

Université Paris-Saclay

FRANCE

View details

Sara Bleve

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

ITALY

View details

Christopher J. Sweeney

University of Adelaide

AUSTRALIA

View details

Eduardo Eyras

Professor

Australian National University

AUSTRALIA

View details

Michael Carducci

Vice Chair, Solid Tumor Oncology

Johns Hopkins University

UNITED STATES

View details

Konrad Tałasiewicz

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Francesco Sanguedolce

Institut de Recerca Sant Pau

SPAIN

View details

Young Deuk Choi

Professor

Yonsei University

SOUTH KOREA

View details

Vincenza Conteduca

Associate Professor

University of Foggia

ITALY

View details

Alonso García Ruiz

Vall d´Hebron Institut d´Oncologia

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Olmos Hidalgo

Research Interests

Explore related searches

Articles (20)

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial

PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.

Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer

Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial

Immunome profiling in prostate cancer: a guide for clinicians

Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide (Prostate Cancer and Prostatic Diseases, (2023), 26, 1, (156-161), 10.1038/s41391-022-00592-9)

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.

Collaborators (15)

Francesco Grussu

Enrique Gonzalez-Billalabeitia

Kim Chi

Satoru Kawakami

Johann S de Bono

Stéphane Oudard

Sara Bleve

Christopher J. Sweeney

Eduardo Eyras

Michael Carducci

Konrad Tałasiewicz

Francesco Sanguedolce

Young Deuk Choi

Vincenza Conteduca

Alonso García Ruiz

Make your next move.